SUPPLEMENTAL FIGURES AND TABLES from Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes
Year: 2023
Type: supplementary-materials
Abstract: Appendix 1: Additional Methods for Subtype Assignment Figure S1. Consistency check between published supervised classification vs. novel unsupervised clustering in TCGA Figure S2. Subclasses were computed by applying a consensus NMF clustering method which confirmed the presence of four stable clusters. Consensus matrices and sample correlation matrices are shown for k=2 to k=8 using the 1500 probe sets based on genes described by TCGA. Figure S3. Kaplan Meier analysis of progression free and overall survival for bevacizumab vs. standard treatment. Panel A: total study population. Panel B: patients at high risk for progression (suboptimally cytoreduced stage III and all stage IV patients) Supplemental Table 1. Results of progression-free survival restricted mean
Authors: Stefan Kommoss, Boris Winterhoff, Ann L. Oberg, Gottfried E. Konecny, Chen Wang, Shaun M. Riska, Jian-Bing Fan, Matthew J. Maurer, Craig April, Viji Shridhar, Friedrich Kommoss, Andreas du Bois, Felix Hilpert, Sven Mahner, Klaus Baumann, Willibald Schroeder, Alexander Burges, Ulrich Canzler, Jeremy Chien, Andrew C. Embleton, Mahesh Parmar, Richard Kaplan, Timothy Perren, Lynn C. Hartmann, Ellen L. Goode, Sean C. Dowdy, Jacobus Pfisterer
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361935184